Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BrainStorm Cell Therapeutics (BrainStorm) has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.
Subscribe to our email newsletter
Hadassah’s Helsinki Committee has approved the commencement of clinical trials with BrainStorm on condition of approval by the National Helsinki Committee of Israel’s Ministry of Health.
The agreement that was signed with Hadassah, through its technology transfer company Hadasit Medical Research Services and Development, calls for the company’s ALS clinical trials to be performed at Hadassah utilising Hadassah’s medical facility and physicians and their experience with injecting patients with mesenchymal stem cells.
The agreement also provides the company with the use of a dedicated laboratory and equipment. Work at the lab will be carried out by the company’s employees under the supervision of the company’s supervisor together with Hadassah’s supervisor of good manufacturing practice standards.
Rami Efrati, CEO of BrainStorm, said: “We are extremely pleased with this agreement with Hadassah. Hadassah is a medical organisation with proficiency in stem cell therapy and has been providing stem cell treatments to patients for quite some time. This agreement provides BrainStorm with the medical expertise and support needed to conduct its first ALS clinical trials at a leading medical center in Israel and the Middle East. Along with the funds we secured last week, we now have in place all that we need to proceed with our ALS clinical trials and only await approval from the Israeli Ministry of Health which we hope we will receive in the coming weeks.”